{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T06:37:43Z","timestamp":1780814263930,"version":"3.54.1"},"reference-count":35,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of this review is to summarise the latest evidence on efficacy and safety of treatments for new-onset atrial fibrillation (NOAF) in critical illness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Critically ill adult patients who developed NOAF during admission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Primary and secondary outcomes<\/jats:title><jats:p>Primary outcomes were efficacy in achieving rate or rhythm control, as defined in each study. Secondary outcomes included mortality, stroke, bleeding and adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched MEDLINE, EMBASE and Web of Knowledge on 11 March 2019 to identify randomised controlled trials (RCTs) and observational studies reporting treatment efficacy for NOAF in critically ill patients. Data were extracted, and quality assessment was performed using the Cochrane Risk of Bias Tool, and an adapted Newcastle-Ottawa Scale.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 1406 studies identified, 16 remained after full-text screening including two RCTs. Study quality was generally low due to a lack of randomisation, absence of blinding and small cohorts. Amiodarone was the most commonly studied agent (10 studies), followed by beta-blockers (8), calcium channel blockers (6) and magnesium (3). Rates of successful rhythm control using amiodarone varied from 30.0% to 95.2%, beta-blockers from 31.8% to 92.3%, calcium channel blockers from 30.0% to 87.1% and magnesium from 55.2% to 77.8%. Adverse effects of treatment were rarely reported (five studies).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The reported efficacy of beta-blockers, calcium channel blockers, magnesium and amiodarone for achieving rhythm control was highly varied. As there is currently significant variation in how NOAF is managed in critically ill patients, we recommend future research focuses on comparing the efficacy and safety of amiodarone, beta-blockers and magnesium. Further research is needed to inform the decision surrounding anticoagulant use in this patient group.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2019-034774","type":"journal-article","created":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T20:25:19Z","timestamp":1585081519000},"page":"e034774","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Managing new-onset atrial fibrillation in critically ill patients: a systematic narrative review"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5565-914X","authenticated-orcid":false,"given":"Liam Joseph","family":"O'Bryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver C","family":"Redfern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9455-022X","authenticated-orcid":false,"given":"Jonathan","family":"Bedford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Petrinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Duncan","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1023-3927","authenticated-orcid":false,"given":"Peter J","family":"Watkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,3,24]]},"reference":[{"key":"2020050713310953000_10.3.e034774.1","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s00134-019-05633-x","article-title":"New-onset atrial fibrillation in adult critically ill patients: a scoping review","volume":"45","author":"Wetterslev","year":"2019","journal-title":"Intensive Care Med"},{"key":"2020050713310953000_10.3.e034774.2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40560-015-0085-4","article-title":"Epidemiology, prevention, and treatment of new-onset atrial fibrillation in critically ill: a systematic review","volume":"3","author":"Yoshida","year":"2015","journal-title":"J Intensive Care"},{"key":"2020050713310953000_10.3.e034774.3","doi-asserted-by":"publisher","DOI":"10.1186\/cc9057"},{"key":"2020050713310953000_10.3.e034774.4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1164\/rccm.201603-0618OC","article-title":"Incidence, predictors, and outcomes of new-onset atrial fibrillation in critically ill patients with sepsis. A cohort study","volume":"195","author":"Klein Klouwenberg","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2020050713310953000_10.3.e034774.5","doi-asserted-by":"crossref","first-page":"326.e1","DOI":"10.1016\/j.jcrc.2011.10.011","article-title":"Epidemiology and management of atrial fibrillation in medical and noncardiac surgical adult intensive care unit patients","volume":"27","author":"Kanji","year":"2012","journal-title":"J Crit Care"},{"key":"2020050713310953000_10.3.e034774.6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jcrc.2017.11.040","article-title":"The impact of sustained new-onset atrial fibrillation on mortality and stroke incidence in critically ill patients: a retrospective cohort study","volume":"44","author":"Yoshida","year":"2018","journal-title":"J Crit Care"},{"key":"2020050713310953000_10.3.e034774.7","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015574726"},{"key":"2020050713310953000_10.3.e034774.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2007.09.005"},{"key":"2020050713310953000_10.3.e034774.9","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000040"},{"key":"2020050713310953000_10.3.e034774.10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15829\/1560-4071-2017-7-7-86","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"147","author":"Kirchhof","year":"2017","journal-title":"Russ J Cardiol"},{"key":"2020050713310953000_10.3.e034774.11","unstructured":"National Institute for Health and Care Excellence . Atrial fibrillation: the management of atrial fibrillation. In: NICE clinical guideline 180. 180th edn. London: NICE Clinical Guidelines, 2014."},{"key":"2020050713310953000_10.3.e034774.12","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181709e43"},{"key":"2020050713310953000_10.3.e034774.13","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jamacardio.2016.2181","article-title":"Practice patterns and outcomes associated with use of anticoagulation among patients with atrial fibrillation during sepsis","volume":"1","author":"Walkey","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2020050713310953000_10.3.e034774.14","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000048627.39686.79"},{"key":"2020050713310953000_10.3.e034774.15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1378\/chest.15-0959","article-title":"Practice patterns and outcomes of treatments for atrial fibrillation during sepsis: a propensity-matched cohort study","volume":"149","author":"Walkey","year":"2016","journal-title":"Chest"},{"key":"2020050713310953000_10.3.e034774.16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s13054-016-1548-2","article-title":"Prognostic impact of restored sinus rhythm in patients with sepsis and new-onset atrial fibrillation","volume":"20","author":"Liu","year":"2016","journal-title":"Crit Care"},{"key":"2020050713310953000_10.3.e034774.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"2020050713310953000_10.3.e034774.18","doi-asserted-by":"crossref","unstructured":"Ouzzani M , Hammady H , Fedorowicz Z , et al . Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 2016;5:210.doi:10.1186\/s13643-016-0384-4","DOI":"10.1186\/s13643-016-0384-4"},{"key":"2020050713310953000_10.3.e034774.19","unstructured":"Elmagarmid A , Fedorowicz Z , Hammady H , et al . Rayyan: a systematic reviews web app for exploring and filtering searches for eligible studies for Cochrane Reviews. In: Evidence-Informed public health: opportunities and challenges Abstracts of the 22nd Cochrane Colloquium. John Wiley & Sons, 2014: 9."},{"key":"2020050713310953000_10.3.e034774.20","unstructured":"Wells GA , Shea B , O\u2019Connell D , et al . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. The Ottawa Hospital Research Institute, 2010."},{"key":"2020050713310953000_10.3.e034774.21","doi-asserted-by":"crossref","unstructured":"Bedford J , Harford M , Petrinic T , et al . Risk factors for new-onset atrial fibrillation on the general adult ICU: protocol for a systematic review. BMJ Open 2018;8:e024640.doi:10.1136\/bmjopen-2018-024640","DOI":"10.1136\/bmjopen-2018-024640"},{"key":"2020050713310953000_10.3.e034774.22","doi-asserted-by":"crossref","unstructured":"Higgins JPT , Altman DG , G\u00f8tzsche PC , et al . The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.doi:10.1136\/bmj.d5928","DOI":"10.1136\/bmj.d5928"},{"key":"2020050713310953000_10.3.e034774.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2017.08.003"},{"key":"2020050713310953000_10.3.e034774.24","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199811000-00004"},{"key":"2020050713310953000_10.3.e034774.25","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199511000-00005"},{"key":"2020050713310953000_10.3.e034774.26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5492\/wjccm.v4.i3.251","article-title":"Landiolol, an ultra-short-acting \u03b21-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis","volume":"4","author":"Okajima","year":"2015","journal-title":"World J Crit Care Med"},{"key":"2020050713310953000_10.3.e034774.27","first-page":"94","article-title":"Diltiazem versus amiodarone for new-onset atrial arrhythmias in non-cardiac post surgical patients: a cohort study","volume":"11","author":"Gerlach","year":"2008","journal-title":"Crit Care Shock"},{"key":"2020050713310953000_10.3.e034774.28","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/BF03040901","article-title":"High-dosage continuous amiodarone therapy to treat new-onset supraventricular tachyarrhythmias in surgical intensive care patients: an observational study","volume":"116","author":"Mayr","year":"2004","journal-title":"Wien Klin Wochenschr"},{"key":"2020050713310953000_10.3.e034774.29","doi-asserted-by":"publisher","DOI":"10.1177\/0885066607310181"},{"key":"2020050713310953000_10.3.e034774.30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13054-016-1252-2","article-title":"Variable use of amiodarone is associated with a greater risk of recurrence of atrial fibrillation in the critically ill","volume":"20","author":"Mitri\u0107","year":"2016","journal-title":"Crit Care"},{"key":"2020050713310953000_10.3.e034774.31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jcrc.2017.04.027","article-title":"Propafenone for supraventricular arrhythmias in septic shock-Comparison to amiodarone and metoprolol","volume":"41","author":"Balik","year":"2017","journal-title":"J Crit Care"},{"key":"2020050713310953000_10.3.e034774.32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jss.2018.03.009","article-title":"Impact and treatment success of new-onset atrial fibrillation with rapid ventricular rate development in the surgical intensive care unit","volume":"229","author":"Brown","year":"2018","journal-title":"J Surg Res"},{"key":"2020050713310953000_10.3.e034774.33","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1378\/chest.15-0358","article-title":"Optimizing atrial fibrillation management: from ICU and beyond","volume":"148","author":"Walkey","year":"2015","journal-title":"Chest"},{"key":"2020050713310953000_10.3.e034774.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021328"},{"key":"2020050713310953000_10.3.e034774.35","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0140-6736(16)31258-2","article-title":"Rate control in atrial fibrillation","volume":"388","author":"Van Gelder","year":"2016","journal-title":"Lancet"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-034774","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T16:15:12Z","timestamp":1601050512000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-034774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3,9]]},"published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1136\/bmjopen-2019-034774"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-034774","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}